Abstract
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Central Nervous System Agents in Medicinal Chemistry
Title: Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Volume: 9 Issue: 1
Author(s): DeRen Huang and Alexander Rae-Grant
Affiliation:
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Abstract: Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Export Options
About this article
Cite this article as:
Huang DeRen and Rae-Grant Alexander, Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152409787601923
DOI https://dx.doi.org/10.2174/187152409787601923 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Chemistry in the Bioactivity of Chlorophylls: An Overview
Current Medicinal Chemistry Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Autosomal Recessive Hereditary Spastic Paraplegia: A Rare Case of a Family with Phenotypic Variation
Current Pharmacogenomics and Personalized Medicine Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets SAMHD1 in Retroviral Restriction and Innate Immune Sensing – Should We Leash the Hound?
Current HIV Research Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Notch Signaling in Cardiovascular Disease and Calcification
Current Cardiology Reviews Severe Preeclampsia
Current Women`s Health Reviews Biologic Therapy in Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry